A Study LY2228820 for Recurrent Ovarian Cancer
Public ClinicalTrials.gov record NCT01663857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer
Study identification
- NCT ID
- NCT01663857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 118 participants
Conditions and interventions
Interventions
- LY2228820 Drug
- Carboplatin Drug
- Placebo Drug
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2012
- Primary completion
- May 24, 2017
- Completion
- May 10, 2018
- Last update posted
- Sep 10, 2019
2012 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Josephs Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| Arizona Oncology Associates, P.C. | Tucson | Arizona | 85710 | — |
| Sarasota Memorial Hospital | Sarasota | Florida | 34239 | — |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Franklin Square Hospital Center | Baltimore | Maryland | 21237 | — |
| Barnes Jewish Hospital | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| SMO Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Austin | Texas | 78731 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Bedford | Texas | 76022 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Fort Worth | Texas | 76104 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78229 | — |
| Texas Oncology - The Woodlands | The Woodlands | Texas | 77380 | — |
| US Oncology | The Woodlands | Texas | 77380 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Northwest Cancer Specialists PC | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01663857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2019 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01663857 live on ClinicalTrials.gov.